02335

Ms. Xiangling Wang is Chief Medical Officer of Shaanxi Micot Pharmaceutical Technology Co. Ltd. from October 2024. Ms. Wang joined the Shaanxi Micot Pharmaceutical Technology Co. Ltd. in October 2024. Ms. Wang is responsible for leading all the clinical development and the related functions. Ms. Wang assumed the role of Clinical Research Director in the Global Medical Operations Department at Sanofi (China) Investment Co., Ltd., a subsidiary of a global pharmaceutical company principally engaged in managing and supporting Sanofi’s pharmaceutical business and clinical development activities in the PRC, serving in this capacity from April 2016 to March 2019. From April 2019 to April 2022, Ms. Wang held the position of Vice President of Clinical Medicine at Visen Pharmaceutical, a biopharmaceutical company focusing on the research, development and commercialisation of therapies for endocrine and metabolic diseases. She subsequently served as the Chief Medical Officer at Hope Medicine inc. from July 2020 to February 2022, a biopharmaceutical company engaged in the R&D of innovative drug candidates in dermatology and other therapeutic areas. From February 2022 to October 2024, Ms. Wang was appointed as Executive Vice President of Clinical Development at Shanghai Bio Genuine Biotech Co., Ltd., a biotechnology company principally engaged in the R&D of innovative biologics. Ms. Wang obtained her bachelor’s degree in clinical medicine from Hunan Medical University (currently known as Xiangya School of Medicine, Central South University in July 1993. She further obtained her master’s degree in clinical medicine from Shantou University Medical College in July 2007.